selank

russian anti-anxiety peptide. head-to-head benzodiazepine trials, lighter sedation signal, thin Western long-term data.

tier B · focus · Russia '04 anxiety registry

verdict

Russian anti-anxiety peptide. head-to-head benzodiazepine trials, allosteric GABA modulation, lighter tolerance signal.

if you're asking how Selank compares to benzodiazepines — Russian trials against medazepam matched anxiolytic efficacy and preserved cognitive and psychomotor function. a 2015 study showed Selank let patients cut benzodiazepine dose while keeping anxiety control. allosteric GABA modulation (not direct receptor binding) is the mechanistic case for why tolerance and dependence look different. community users describe lower baseline anxiety without the fog of classic anxiolytics.

if you're asking what to trust the long-term safety on — Russian clinical use is decades long without a major signal. Western long-term data is thin. allosteric modulation makes the lighter-tolerance claim mechanistically plausible; it doesn't substitute for completed Western trials. recent broad reviews have not upgraded Selank beyond its Russian clinical record.

if you came in via the immunomodulator framing — Selank retains tuftsin's immune effects on macrophages and NK cells. that's a real piece of the molecule. it's also not what most users come to it for, and the immunomodulator evidence is preclinical and small-trial. better evidenced than most peptides marketed for anxiety; less validated than the hype implies.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because the evidence is real: Russian regulatory approval, comparison trials against established benzodiazepines, multi-pathway mechanism documentation. But it's structured outside Western clinical recognition. The absence of FDA or EMA evaluation means most Western clinicians have no framework for considering it, despite strong evidence by the standards that produced its original approval. If Western regulatory attention ever reaches Selank the way it's reaching Semax in 2026, tier placement would likely move up.

the core tension

Selank is Semax's sister peptide from the same Russian lab, approved for generalized anxiety disorder in Russia. It shows anxiolytic effects comparable to medazepam in clinical comparison trials, with a lighter sedation story than the benzodiazepine lane. The mechanism is unusual: part allosteric GABA modulation, part immunomodulation from its tuftsin origin. Almost unknown in Western clinical medicine despite having more human trial data than most anxiolytic peptides.

what it is

a synthetic heptapeptide built from tuftsin, a natural immune peptide cleaved from human IgG, plus the same Pro-Gly-Pro stability tail Semax uses. approved in Russia in 2009 for generalized anxiety disorder and neurasthenia. intranasal 0.15% spray. not FDA-approved, not under review.

what it does

modulates GABA allosterically instead of binding the receptor directly. that is the mechanistic case for why tolerance and dependence look different from benzodiazepines. it also touches serotonin, dopamine, BDNF, and enkephalinase, and retains tuftsin's immune effects on macrophages and NK cells. the pitch is anxiolysis without the sedation. western long-term data has not yet settled that pitch at label strength.

origin

built at the Institute of Molecular Genetics with the V.V. Zakusov Institute of Pharmacology. same team, same era as Semax. the curious part: tuftsin was supposed to be an immune peptide. the stability tail was supposed to just extend half-life. the finished molecule turned out anxiolytic, and the parent peptide was not.

why researchers are interested

russian trials against medazepam matched anxiolytic efficacy and preserved cognitive and psychomotor function. a 2015 study showed selank let patients cut benzodiazepine dose while keeping anxiety control. community users describe lower baseline anxiety without the fog of classic anxiolytics. side effects are usually mild nasal irritation.

does it work

the clinical story is real and the head-to-head benzodiazepine design is more rigorous than placebo-only would have been. allosteric GABA modulation makes the lighter tolerance and dependence claim mechanistically plausible. the catch is exactly Semax's catch. most primary literature is Russian, no FDA evaluation, no Western regulatory framework. recent broad reviews have not upgraded selank beyond its Russian clinical record. the modern English-language literature still leans mechanistic and preclinical. better evidenced than most peptides marketed for anxiety. less validated than the hype implies.

claims vs the data

• anxiolytic without sedation or cognitive impairment — supported — Russian comparison trials against medazepam showed comparable anxiolytic effect with preserved psychomotor and cognitive function. This is the primary basis for the Russian regulatory approval.
• less tolerance or dependency risk than benzodiazepines — partially true — Russian clinical studies and prescription use report little tolerance or dependence signal, and allosteric GABA modulation makes the claim plausible. Western-style long-term datasets remain thin.
• enhances cognitive function while reducing anxiety — partially true — Russian trials show combined anxiolytic and cognitive effects in GAD patients. Effects in healthy cognitive-enhancement contexts are less clearly established than Semax but community reports are consistent.
• upregulates BDNF like Semax — supported — Multiple studies confirm BDNF mRNA elevation in hippocampus and frontal cortex after Selank administration. Shared mechanism with Semax, though Selank skews more anxiolytic in practice.
• immunomodulatory (enhances NK cell and phagocyte activity) — supported — Retains parent tuftsin's immune properties. Documented effects on IL-6, Th1/Th2 balance, and phagocytic activity. The mechanistic bridge between immune modulation and anxiolytic effects is genuinely novel.
• safe for long-term daily use — partially true — Russian prescription use has not produced a loud serious-safety signal, but Western long-term data is thin. Reported side effects are usually mild, especially nasal irritation from spray formulations.

key facts

• molecular formula: C33H57N11O9
• molecular weight: 751.9 Da
• amino acids: 7
• half-life: minutes in plasma; effects last hours due to neurological cascade
• type: heptapeptide (tuftsin analog + PGP extension)
• CAS: 129954-34-3
• 2009 Russian regulatory approval (GAD)
• =medazepam anxiolytic efficacy in comparison trials
• thin Western long-term tolerance data
• ~10 min plasma clearance; effects persist longer

frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. Developed at the Institute of Molecular Genetics in Moscow. It is registered in Russia as an intranasal anxiolytic medicine and marketed through Russian pharmacies. It is not FDA-approved in the United States.

What does Selank do?

Produces anxiolytic effects with less sedation and cognitive dulling than classic benzodiazepine framing suggests. Mechanism involves GABAergic modulation and BDNF/neurotrophin effects. Russian clinical trials support efficacy in generalized anxiety; Western long-term datasets are much thinner.

How is Selank typically administered?

Selank is approved for clinical use in Russia as an intranasal formulation, with dosing determined by prescribing physicians under that regulatory regime. There is no FDA-approved dosing protocol in the United States. This site does not provide dosing guidance for compounds not approved by the FDA.

What are the side effects of Selank?

Side effect reports are usually mild, most commonly nasal irritation from drops. Russian clinical data suggests a favorable tolerability profile compared with traditional anxiolytics, but the no-dependence and no-tolerance story is less characterized in Western-style long-term datasets.

Is Selank FDA approved?

No. Selank is not FDA-approved in the United States. It is approved in Russia as a prescription anxiolytic medication.

How much does Selank cost?

No US clinical retail price exists. On the research-chemical market it is inexpensive, varying by strength. Russian pharmacy formulations are available via international import.

related peptides

• semax — sister peptide from same Russian lab, cognitive-leaning
• oxytocin — another social/anxiolytic peptide with thin Western human data
• dsip — Russian-adjacent sleep/stress peptide

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.